October 2021

Positive phase 2 data resulted in a breakthrough therapy designation for donanemab, (Eli Lilly), prompting a biologics license application submission for the agent.

In a NeurologyLive® Insights series, experts in the diagnosis and treatment of Dravet syndrome discussed the management of the disease and the utilization of approved treatments to improve outcomes in patients.

Although headache and COVID-19 have been linked together in the literature, more studies are needed to better understand the pathophysiology of these headaches and to determine the best treatment options.

Mitchell S. V. Elkind, MD, MS, MPhil, shared his perspective and offered insights into the recent updates from the American Heart Association/American Stroke Association on the landscape of stroke prevention and poststroke care.

Continued improvement in the pharmacodynamics and pharmacokinetics of S1PR modulators, particularly in modulator-receptor selectivity, should improve therapeutic efficacy while reducing the potential for AEs.

Previously, many promising treatments for PD have ultimately resulted in untenable adverse effects or in failure, but the evolving area of protein folding offers an opportunity to slow or reverse the neurodegenerative process.

Excessive daytime sleepiness is a hallmark of a number of sleep disorders, and ensuring the proper diagnosis and management of those presenting with it is crucial to care.

Years of built-up trust in the community has enabled Montefiore’s Stern Stroke Center physicians to understand more about how stroke affects multicultural communities and to break down existing barriers to care.

Proper diagnosis and effective treatment planning can drastically improve quality of life for individuals with migraine.